Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Epoch Investment Partners Inc.

Epoch Investment Partners Inc. reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 8.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 778,311 shares of the biopharmaceutical company's stock after selling 74,956 shares during the period. Epoch Investment Partners Inc. owned approximately 0.61% of Halozyme Therapeutics worth $37,211,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Heck Capital Advisors LLC bought a new stake in Halozyme Therapeutics in the 4th quarter worth about $29,000. CBIZ Investment Advisory Services LLC bought a new position in Halozyme Therapeutics during the fourth quarter valued at approximately $29,000. Smartleaf Asset Management LLC boosted its holdings in Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 197 shares during the last quarter. Venturi Wealth Management LLC bought a new stake in Halozyme Therapeutics in the 4th quarter worth approximately $69,000. Finally, Parkside Financial Bank & Trust raised its stake in Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after buying an additional 322 shares during the last quarter. Institutional investors own 97.79% of the company's stock.

Insider Activity at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now owns 173,756 shares of the company's stock, valued at $10,126,499.68. This represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jeffrey William Henderson sold 503 shares of Halozyme Therapeutics stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total transaction of $32,217.15. Following the completion of the transaction, the director now directly owns 33,108 shares in the company, valued at $2,120,567.40. This represents a 1.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 22,200 shares of company stock valued at $1,286,568 over the last quarter. 2.90% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a report on Friday. Piper Sandler upped their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research note on Friday, January 10th. Benchmark reiterated a "buy" rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. JPMorgan Chase & Co. raised their price objective on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research note on Monday. Finally, Wells Fargo & Company lowered their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, Halozyme Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $62.89.

Halozyme Therapeutics Stock Up 2.4 %

Halozyme Therapeutics stock traded up $1.42 during midday trading on Friday, hitting $60.67. 364,927 shares of the company's stock were exchanged, compared to its average volume of 1,429,892. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The company has a market cap of $7.49 billion, a PE ratio of 17.66, a P/E/G ratio of 0.42 and a beta of 1.32. The firm has a 50-day moving average of $60.43 and a two-hundred day moving average of $55.01. Halozyme Therapeutics, Inc. has a 12 month low of $37.97 and a 12 month high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. As a group, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.